Key facts
- It has raised $7.3M; the latest was Early Stage VC ($7.3M) in Mar 2026.
- Notable investors include Yonghua Capital, Yunqi Partners, BioMap, Eminence Ventures, Inno-Chip.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for C12.ai
- ·The full record, as it builds
Funding rounds
No funding rounds for C12.ai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About C12.ai
Provider of intelligent laboratory automation services intended for pharmaceutical research purposes. The company offers artificial intelligence for drug discovery workflows, embodied intelligence for robotic handling, and advanced data processing capabilities, enabling pharmaceutical laboratories to reduce reliance on manual operations, improve reproducibility of experiments, and accelerate development timelines.
- Sector
- Information Technology
- HQ
- Shanghai, China
- Website
- c12.ai/en
- Ownership
- Privately Held (backing)
C12.ai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in C12.ai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on C12.ai in its N-PORT filings yet. We sweep new filings monthly.